Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Z-Endoxifen · NSC-749798

Small molecule · developed by Atossa Therapeutics

Phase 2 Most advanced trial (none active)
ATOS Developer
1 Registered trials

What is Z-Endoxifen?

Z-Endoxifen is the Z-isomer of endoxifen, a metabolite of tamoxifen. It is studied in breast density, a measure of breast tissue composition relevant to breast cancer risk.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NSC-749798
Drug type
Small molecule
Therapy area
Women's health
Developer
Atossa Therapeutics, Inc. (ATOS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
46AF8680RC

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05068388 Phase 2 Breast Density Completed ATOS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Breast Density

More from Atossa Therapeutics

AT-301A Phase 1 AT-301B Phase 1 Endoxifen Phase 2

Follow ATOS, the company behind Z-Endoxifen

See ATOS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ATOS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.